EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommended public offer to the shareholders of OX2 AB (publ) (“OX2”). The shares are admitted to trading on Nasdaq Stockholm, Large Cap.

OX2, founded in 2004, is a leading renewable energy platform with a large and diverse project portfolio across all major renewable energy technologies (onshore and offshore wind, solar, and storage) and is today one of the largest developers of onshore wind in Europe.

The total value of the offer is approximately SEK 16.4 billion.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Linnéa Sellström, Joel Magnusson, Lorin Arabi and Maximilian Bengtsson (apital Markets and Public M&A), Christoffer Thalin, Peter Sundgren, Filip Öhrner, Daniel Daun, Niklas Törnell and Jonatan Karlsson (Energy, M&A), Sebastian Örndahl, Hampus Peterson, Lovisa Lewin and Ebba Ehrling Sjögren (Regulatory), Kamyar Najmi (Banking and finance), Lina Österberg, Tilda Hall and Agnes Pigg (Environment and Real Estate) Sam Seddigh and Alice Göransson (Employment), Fredrika Hjelmberg and Ian Linde (IT/GDPR), Gulestan Ali (Compliance) and Julia Ulander Kull (Transaction Support Coordinator).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025